The study presents an in-depth exploration of novel functional ingredients designed to enhance mental and emotional well-being, identifying the overall drivers of growth, technological change, and market opportunities through 2030. Mental health disorders continue to present a serious global challenge, with anxiety and depression affecting more than 1 billion individuals worldwide. This indicates only intensifying demand for interventions that are both effective and can be employed on demand and routinely. Innovation is now occurring in pharmacological therapies, digital therapeutics, new AI-driven personalized care models, and natural botanical therapies and supplements are entering the marketplace to address therapy gaps. The incorporation of small molecules, injectables, digital therapeutics and monitoring tools, and nootropic formulations is driving growth and innovation in the treatment of mental health and emotional well-being. Corporate- and employer-branded investments in employee mental well-being, along with changing regulatory requirements, will contribute to the market opportunity. While some challenges remain related to workforce, stigma, and access, precision psychiatry and technology-driven AI-based mental health diagnostics and monitoring can indicate better future outcomes. Lastly, the report will examine the competitive landscape, funding, partnerships, and new therapies to provide useful directions for stakeholders interested in the expanding mental health and emotional well-being space.